Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$3.01
-1.8%
$2.97
$2.30
$5.54
$184.44M-0.16313,648 shs194,685 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$2.77
+4.5%
$2.21
$1.67
$10.03
$679.94M0.282.28 million shs878,186 shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.20
+9.4%
$2.32
$1.26
$7.40
$719.27M1.863.75 million shs6.18 million shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$11.49
-0.6%
$10.43
$5.35
$16.15
$626.77M1.14672,441 shs185,804 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-1.80%+9.27%-5.21%+6.18%+22.15%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
+4.49%+16.34%+24.73%+42.73%-60.39%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
+9.42%+11.32%+36.54%+115.88%-38.79%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-0.56%-3.00%+5.37%+93.35%-9.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
2.0149 of 5 stars
3.54.00.00.00.01.70.0
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
3.4779 of 5 stars
3.12.00.04.40.60.80.6
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.7835 of 5 stars
3.51.00.00.02.63.30.6
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
4.0327 of 5 stars
3.60.00.04.82.30.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
3.00
Buy$9.00199.50% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.25
Hold$6.64139.76% Upside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
3.00
Buy$9.17186.91% Upside
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.29
Buy$23.20102.00% Upside

Current Analyst Ratings Breakdown

Latest ELDN, STOK, SANA, and MRVI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00
7/1/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/24/2025
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00
6/18/2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$9.00
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $35.00
5/13/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
5/13/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.00
4/24/2025
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/9/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$1.98 per shareN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$259.18M2.72$0.64 per share4.32$2.28 per share1.21
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$1.12 per shareN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$36.56M17.15N/AN/A$4.32 per share2.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$144.85M-$1.14N/AN/AN/A-67.14%-12.91%-6.87%8/6/2025 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$266.76M-$0.88N/AN/AN/AN/A-86.58%-44.49%8/6/2025 (Estimated)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$88.98M$0.7914.54N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)

Latest ELDN, STOK, SANA, and MRVI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.28-$0.08+$0.20-$0.08N/AN/A
5/12/2025Q1 2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million
5/8/2025Q1 2025
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.22-$0.20+$0.02-$0.21N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
13.90
13.91
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.60
5.96
5.17
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
3.40
3.40
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
8.41
8.41

Institutional Ownership

CompanyInstitutional Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
12.30%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.11%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
30.10%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
9.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1059.88 million52.52 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
610254.66 million249.29 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
380225.48 million157.61 millionOptionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10054.60 million49.41 millionOptionable

Recent News About These Companies

Stockley named Stoke's new academy manager
STOK Stoke Therapeutics, Inc. - Seeking Alpha
Cantor Fitzgerald Predicts STOK FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$3.00 -0.06 (-1.80%)
As of 07/3/2025 01:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$2.77 +0.12 (+4.49%)
Closing price 07/3/2025 03:08 PM Eastern
Extended Trading
$2.72 -0.05 (-1.95%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$3.20 +0.28 (+9.42%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$3.19 0.00 (-0.03%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$11.48 -0.07 (-0.56%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$11.48 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.